Bioequivalence study in healthy volunteers.
Conditions
Interventions
Intervention 1: Intervention group 1, which consists of 24 healthy and fasting volunteers, will receive a tablet with a dose of 500 mg manufactured by Iran hormone Pharmaceutical Company. Intervention
Sponsors
Iran hormone
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: The weight range of participating candidates should be between 60-100 kg Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose. Volunteers who have agreed to an informed consent form. All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw
Exclusion criteria
Exclusion criteria: History of allergic or adverse reaction to Valaciclovir or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s) Smokers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of the drug. Timepoint: 16 sampling time till 12 h. Method of measurement: En Liquid Chromatography with tandem mass spectrometry (LC-MS-MS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehrdad Hamidi
Zanjan University of Medical Sciences
Outcome results
None listed